Cargando…

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents

BACKGROUND/AIMS: Although mucosal healing (MH) is acknowledged as the treatment target in the treat-to-target era, there are limitations on repeated endoscopic examinations, especially in pediatric patients. We aimed to investigate whether fecal calprotectin (FC) could serve as a surrogate marker fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yoo Min, Choi, Sujin, Choe, Byung-Ho, Jang, Hyo-Jeong, Kim, Seung, Koh, Hong, Kim, Eun Sil, Kim, Mi Jin, Choe, Yon Ho, Kang, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761923/ https://www.ncbi.nlm.nih.gov/pubmed/33833135 http://dx.doi.org/10.5009/gnl20300

Ejemplares similares

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease
por: Lee, Yeoun Joo, et al.
Publicado: (2022)

Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
por: Kim, Eun Sil, et al.
Publicado: (2022)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Fecal Calprotectin Levels Significantly Correlate with Polyp Size in Children and Adolescents with Juvenile Colorectal Polyps
por: Kim, Yu Bin, et al.
Publicado: (2023)

Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
por: Park, Sowon, et al.
Publicado: (2022)

Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis
por: Chen, Fang, et al.
Publicado: (2021)

Potential Utility of Fecal Calprotectin in Discriminating Colorectal Polyps From Other Major Etiologies in Children Presenting With Isolated Hematochezia
por: Kim, Yu Bin, et al.
Publicado: (2022)

Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Schönlein purpura patients: a retrospective analysis
por: Paek, Eun Young, et al.
Publicado: (2020)

Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn’s disease than in European patients
por: Kim, Eun Sil, et al.
Publicado: (2020)

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
por: Choi, Sujin, et al.
Publicado: (2022)

Change in the treatment strategy for pediatric Crohn's disease
por: Kim, Mi Jin, et al.
Publicado: (2010)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
por: Ryu, Dae Gon, et al.
Publicado: (2019)

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
por: Kim, Eun Sil, et al.
Publicado: (2021)

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
por: Kristensen, Vendel, et al.
Publicado: (2017)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn’s Disease
por: Kim, Eun Soo
Publicado: (2021)

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease
por: Kennedy, Nicholas A., et al.
Publicado: (2019)

Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial
por: Aniwan, Satimai
Publicado: (2022)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis
por: Hu, Tingpeng, et al.
Publicado: (2023)

The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn’s Disease
por: Ha, Changhee, et al.
Publicado: (2020)

Fecal Calprotectin Is Increased in Stroke
por: Park, Shin Young, et al.
Publicado: (2021)

Can fecal calprotectin better stratify Crohn’s disease activity index?
por: Scaioli, Eleonora, et al.
Publicado: (2015)

Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
por: Romero-Mascarell, Cristina, et al.
Publicado: (2022)

Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Fecal calprotectin concentration in neonatal necrotizing enterocolitis
por: Yoon, Jung Min, et al.
Publicado: (2014)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
por: Lee, Sun-Ho, et al.
Publicado: (2017)

Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease
por: Kim, Hyeon-A, et al.
Publicado: (2019)

Characterization of the fecal microbiota differs between age groups in Koreans
por: Kook, Sun-Young, et al.
Publicado: (2018)

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)

Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn’s disease
por: Somwaru, Alexander S., et al.
Publicado: (2019)

Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn’s disease
por: Li, Junrong, et al.
Publicado: (2023)

Effect of the Crohn’s Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn’s Disease
por: Matuszczyk, Małgorzata, et al.
Publicado: (2022)

Development of Crohn’s Disease in a Child With SLC26A3-related Congenital Chloride Diarrhea: Report of the First Case in East Asia and a Novel Missense Variant
por: Kim, Eun Sil, et al.
Publicado: (2021)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5hr3710e5ep21qhk047n5rb19